Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

August 11, 2017: By Jon Swedien
Bausch + Lomb's Stellaris Elite

Bausch + Lomb’s Stellaris Elite

Bausch + Lomb has launched the Stellaris Elite vision enhancement system for retinal surgery in the US, the Bridgewater, New Jersey-based company announced Aug. 7.

The Stellaris Elite platform builds on B+L’s Stellaris PC, a dual-function cataract/vitrectomy machine commercialized in 2010. The FDA gave the Stellaris Elite 501(k) clearance in April.

The new system features the ability to seamlessly integrate future technologies, such as the Vitesse hypersonic vitrectomy system, which will be exclusive to the Stellaris Elite, B+L said.

The Vitesse system is the first and only hypersonic, 100 percent open port vitrectomy platform, B+L said.

Stellaris Elite machines configured for retinal surgery will come equipped with the Vitesse technology, while the Vitesse hand-piece is slated to be released commercially in late 2017.

The Stellaris Elite offers a variety of vitrectomy cutters operating up to 7,500 cuts per minute (cpm), B+L said. The system will feature a new 27-gauge BiBlade vitrectomy cutter that offers cut rates up to 15 thousand cpm and features an open-port design resulting in a higher, more consistent flow rate than single port cutters, B+L said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023